Zogenix (ZGNX) Tops Q1 EPS by 2c, Revenues Beat

Zogenix (NASDAQ: ZGNX) reported Q1 EPS of ($1.00), $0.02 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $13.68 million versus the consensus estimate of $12.33 million.

“We are pleased with the continued positive momentum in our U.S. launch of FINTEPLA® in Dravet Syndrome, where we see increased adoption by existing and new prescribers and patients,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix. “Our dialogue with U.S. payors is progressing very well, as we work to expand access for patients who could benefit from FINTEPLA treatment. In Europe, our initial launch in Germany has begun in an encouragingly strong manner and our recently established Zogenix Access Program will expand access to FINTEPLA for physicians globally, including in European countries where reimbursement has not yet been established. Additionally, we are working to submit an NDA in Japan for FINTEPLA in the second half of this year.”

“We have the opportunity to potentially make FINTEPLA available to additional patients in need in multiple additional indications, and remain on track to submit global regulatory filings in Lennox-Gastaut syndrome (LGS) later this year and anticipate meeting with the FDA this quarter to discuss the planned Phase 3 trial for CDKL5 deficiency disorder,” continued Dr. Farr. “Lastly, in our MT1621 program for TK2 deficiency, we continue to prepare for an NDA filing in the first half of 2022.”

For earnings history and earnings-related data on Zogenix (ZGNX) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Reading (RDI) Tops Q2 EPS by 4c